This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InterMune Lung Drug Rejected by FDA

InterMune story updated to reflect the stock price's drop in afterhours trading.

BRISBANE, Calif. ( TheStreet) -- Federal regulators rejected InterMune's (ITMN) lung drug pirfenidone Tuesday, asking the company to conduct an additional clinical trial.

InterMune was seeking approval for pirfenidone as a treatment for idiopathic pulmonary fibrosis (IPF), a fatal lung disease. The FDA's decision not to approve pirfenidone at this time comes after an advisory panel in March recommended the drug's approval, albeit with a mixed vote.

InterMune shares were halted Tuesday around 1 p.m. at $45.44; in afterhours trading the stock had plummeted more than 80% to $8.86.

"After the positive FDA advisory committee meeting of March 9 at which the committee recommended the approval of the pirfenidone NDA by a 9-3 margin, we are disappointed by this outcome," said Dan Welch, InterMune's CEO, in a statement.

Intermune plans to meet with FDA to discuss ways to get pirfenidone approved, the company said.

IPF is a disease marked by scarring of the lungs caused by the gradual buildup of fibrous tissue. As the fibrotic scar tissue accumulates, air sacs in the lungs lose their ability to transfer oxygen into the bloodstream. There are no effective treatments for IPF, and unless patients can undergo a successful lung transplant, they eventually die of the disease.

InterMune is hoping that pirfenidone will become the first drug approved for IPF by the FDA and its counterparts in Europe. With well over 200,000 IPF patients in the U.S. and Europe, InterMune could easily transform pirfenidone into a highly profitable drug with more than $1 billion in peak sales.

Pirefenidone is approved as an IPF treatment in Japan, where the drug is sold by Japanese drug maker Shionogi & Co.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ITMN $73.89 -0.03%
AAPL $125.32 -0.38%
FB $78.57 1.30%
GOOG $530.11 -0.13%
TSLA $231.86 -0.47%

Markets

DOW 17,887.49 -40.71 -0.23%
S&P 500 2,084.74 -4.72 -0.23%
NASDAQ 4,929.1890 -10.1380 -0.21%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs